Alpha Tau to Present First Pancreatic Cancer Data at Major Gastroenterology Conference
DRTS has more than doubled off its 52-week low of $2.3.
Summary
Alpha Tau Medical announced that clinical trial data for its Alpha DaRT therapy in pancreatic cancer patients has been accepted for its first-ever oral presentation at Digestive Disease Week (DDW) 2026, a premier international gastroenterology conference.
Key Events · Product Development and Regulatory · DRTS
-
Oral Presentation Acceptance
An abstract presenting results from two clinical trials of Alpha DaRT in pancreatic cancer patients has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026.
-
First-Ever Pancreatic Cancer Data Presentation
This marks the first time clinical results of Alpha DaRT in pancreatic cancer patients have been selected for presentation at a major gastroenterology conference, highlighting the potential of the technology for this devastating disease.
-
Upcoming Data Disclosure
The presentation, titled 'Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma,' will occur on May 2, 2026, where the full data will be presented.
Analysis · DRTS · Industrial Applications And Services
Alpha Tau Medical's announcement of an oral presentation for its Alpha DaRT pancreatic cancer data at Digestive Disease Week (DDW) 2026 is a significant positive development. This marks the first time clinical results for Alpha DaRT in pancreatic cancer will be presented at a major gastroenterology conference, indicating growing scientific recognition and potential for the technology in a challenging disease area. While the full data will be presented in May, the acceptance for an oral presentation validates the company's clinical progress and could increase visibility for its innovative alpha-radiation therapy.
At the time of this filing, DRTS was trading at $6.61 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $576.5M. The 52-week trading range was $2.30 to $8.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.